Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. |
| |
Authors: | Dong Xie Dong Yin He-Jing Wang Gen-Tao Liu Robert Elashoff Keith Black H Phillip Koeffler |
| |
Affiliation: | Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California-Los Angeles (UCLA) School of Medicine, Los Angeles, California 90048, USA. xied@ucla.edu |
| |
Abstract: | The biological properties of CCN proteins include stimulation of cell proliferation, migration, and adhesion, as well as angiogenesis and tumorigenesis. We quantified CYR61, CTGF, WISP-1, and NOV mRNA expression levels in samples from sixty-six primary gliomas and five normal brain samples using quantitative real-time PCR assay. Statistical analysis was performed to explore the links between expression of the CCN genes and clinical and pathological parameters. Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively. Interestingly, significant associations were found between CYR61 expression versus tumor grade, pathology, gender, and age at diagnosis. Also, a significant correlation existed between CTGF mRNA levels versus tumor grade, gender, and pathology. In contrast to CYR61 and CTGF, no significant association was found between expression of either WISP-1 or NOV versus any of the pathological features. Furthermore, Cox regression analysis showed that CYR61 and CTGF expression had a significant correlation with patient survival. These results suggest that CYR61 and CTGF may play a role in the progression of gliomas; their levels at diagnosis may have prognostic significance; and these proteins might serve as valuable targets for therapeutic intervention. |
| |
Keywords: | |
|
|